Keyphrases
Randomized Trial
100%
Systemic Lupus Erythematosus
100%
Clinical Response
100%
Rituximab
100%
Belimumab
100%
B Cell-targeted Therapy
100%
Anti-double-stranded DNA Antibodies
71%
IgA2
71%
Antibody Concentration
57%
Placebo
28%
Between-group Difference
28%
Mean Group
28%
Clinical Trials
14%
Machine Learning
14%
Randomized Controlled Trial
14%
Cell number
14%
Plasmablast
14%
Clinical Features
14%
Autoimmune Disease
14%
Renal Disease
14%
Placebo Groups
14%
Disease Activity
14%
Response Predictors
14%
Disease-associated
14%
Clinical Data
14%
Serum interleukin-6
14%
Renal Involvement
14%
Targeted Therapy
14%
Mucocutaneous Involvement
14%
IgA1
14%
Immune Dysregulation
14%
Mucocutaneous Diseases
14%
Lupus Erythematosus
14%
Molecular Network
14%
Clinical Biomarkers
14%
Advanced Therapies
14%
Biomarkers of Response
14%
Concentration-response
14%
Organ Involvement
14%
T Follicular Helper Cells
14%
Organ Response
14%
Immune Profile
14%
Personalized Approach
14%
Precision Targeting
14%
Laboratory Biomarkers
14%
Immune Abnormalities
14%
Medicine and Dentistry
B Cell
100%
Biological Marker
100%
Systemic Lupus Erythematosus
100%
Targeted Therapy
100%
Rituximab
100%
Belimumab
100%
Double Stranded DNA Antibody
71%
Placebo
42%
Immunity
28%
Clinical Trial
14%
Nephropathy
14%
Randomized Controlled Trial
14%
Autoimmune Disease
14%
Disease Activity
14%
Clinical Feature
14%
Interleukin 6
14%
Plasmablast
14%
Immune Dysregulation
14%
Lupus Vulgaris
14%
Advanced Therapy
14%
T Follicular Helper Cell
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Systemic Lupus Erythematosus
100%
Rituximab
100%
Belimumab
100%
Double Stranded DNA Antibody
71%
Placebo
42%
Clinical Trial
14%
Randomized Controlled Trial
14%
Interleukin 6
14%
Disease Activity
14%
Kidney Disease
14%
Autoimmune Disease
14%
Clinical Feature
14%
Lupus Vulgaris
14%
Immune Dysregulation
14%
Diseases
14%
Immunology and Microbiology
B Cell
100%
Systemic Lupus Erythematosus
100%
Rituximab
100%
Belimumab
100%
Double Stranded DNA Antibody
71%
Antibody Blood Level
57%
Immunity
28%
Plasmablast
14%
Autoimmune Disease
14%
Interleukin 6
14%
Follicular B Helper T Cells
14%
Lupus Vulgaris
14%
Immune Dysregulation
14%
Neuroscience
B Cell
100%
Systemic Lupus Erythematosus
100%
Rituximab
100%
Belimumab
100%
Double Stranded DNA Antibody
71%
Placebo
42%
Interleukin 6
14%
Randomized Controlled Trial
14%
Lupus Erythematosus
14%
Autoimmune Disease
14%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Rituximab
100%
Belimumab
100%
Antibody Blood Level
57%
Immunity
42%
Randomized Controlled Trial
14%
Interleukin 6
14%
Clinical Trial
14%
Molecular Network
14%
Follicular B Helper T Cells
14%